Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer

Inclusion Criteria:

* Histologically or cytologically confirmed adenocarcinoma of the male or female breast (male or female) with gross, uncontrolled, unresectable breast and/or chest wall disease including:

  1. patients with locally advanced unresectable stage IIIa or IIIb;
  2. patients with locally recurrent (including locoregional lymph nodes) disease for which curative surgery is not thought possible
  3. patients with metastatic disease AND uncontrolled locoregional disease are eligible.
* Prior chemotherapy allowed, except for nitrosoureas and mitomycin chemotherapy or high dose chemotherapy with marrow or stem cell rescue.
* Prior palliative radiation to sites of metastases allowed (i.e. bone, brain, lung)
* 4 weeks since any prior treatments (excluding hormonal therapy). Concurrent hormonal therapy is not allowed.
* Aged 18 years or older
* CALGB performance status of 0 - 2
* Life expectance of at least 12 weeks
* Initial Laboratory Data:

  * ANC Count \> 1500/mm3
  * Platelet Count \> 100,000/mm3
  * Creatine ≤ 2.0 mg/dl
  * Bilirubin ≤ 1.5 mg/dl
  * ALT (SGPT) ≤ 3 times the upper limit of normal
* Signed informed consent

Exclusion Criteria:

* Prior breast or chest wall radiation is not allowed unless the proposed site radiation port does not overlap with prior ports
* Subjects must not be pregnant (females able to have children must have negative pregnancy test and agree to use adequate contraception)
* Patients with a documented hypersensitivity to E.coli derived proteins are excluded.
* No other serious medical condition such as uncontrolled infection that in the opinion of the investigators places patient at undue risk for study treatment